• 1
    Engel SG,Corneliussen SJ,Wonderlich SA,Crosby RD,le Grange D,Crow S, et al. Impulsivity and compulsivity in bulimia nervosa. Int J Eat Disord 2005; 38: 244251.
  • 2
    Kaye WH,Fudge JL,Paulus M. New insights into symptoms and neurocircuit function of anorexia nervosa. Nature Rev 2009; 10: 573584.
  • 3
    Morgan JC,Wolfe BE,Metzger ED,Jimerson DC. Obsessive-compulsive characteristics in women who have recovered from bulimia nervosa. Int J Eat Disord 2007; 40: 381385.
  • 4
    Kaye W,Strober M,Stein D,Gendall K. New directions in treatment research of anorexia and bulimia nervosa. Biol Psychiatry 1999; 45: 12851292.
  • 5
    Kaye WH,Frank GK,Meltzer CC,Price JC,McConaha CW,Crossan PJ, et al. Altered serotonin 2A receptor activity in women who have recovered from bulimia nervosa. Am J Psychiatry 2001; 158: 11521155.
  • 6
    Kaye WH,Greeno CG,Moss H,Fernstrom J,Fernstrom M,Lilenfeld LR, et al. Alterations in serotonin activity and psychiatric symptoms after recovery from bulimia nervosa. Arch Gen Psychiatry 1998; 55: 927935.
  • 7
    Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord 1998; 51: 215235.
  • 8
    Tauscher J,Pirker W,Willeit M,de Zwaan M,Bailer U,Neumeister A, et al. [123I] beta-CIT and single photon emission computed tomography reveal reduced brain serotonin transporter availability in bulimia nervosa. Biol Psychiatry 2001; 49: 326332.
  • 9
    Kuikka JT,Tammela L,Karhunen L,Rissanen A,Bergstrom KA,Naukkarinen H, et al. Reduced serotonin transporter binding in binge eating women. Psychopharmacology 2001; 155: 310314.
  • 10
    Bailer UF,Frank GK,Henry SE,Price JC,Meltzer CC,Becker C, et al. Serotonin transporter binding after recovery from eating disorders. Psychopharmacology 2007; 195: 315324.
  • 11
    Steiger H,Richardson J,Israel M,Ng Ying Kin NM,Bruce K,Mansour S, et al. Reduced density of platelet-binding sites for [3H]paroxetine in remitted bulimic women. Neuropsychopharmacology 2005; 30: 10281032.
  • 12
    Frankle WG,Huang Y,Hwang DR,Talbot PS,Slifstein M,Van Heertum R, et al. Comparative evaluation of serotonin transporter radioligands 11C-DASB and 11C-McN 5652 in healthy humans. J Nuclear Med 2004; 45: 682694.
  • 13
    Frankle WG,Slifstein M,Gunn RN,Huang Y,Hwang DR,Darr EA, et al. Estimation of serotonin transporter parameters with 11C-DASB in healthy humans: Reproducibility and comparison of methods. J Nuclear Med 2006; 47: 815826.
  • 14
    Bailer UF,Frank GK,Henry SE,Price JC,Meltzer CC,Weissfeld L, et al. Altered brain serotonin 5-HT1A receptor binding after recovery from anorexia nervosa measured by positron emission tomography and [carbonyl11C]WAY-100635. Arch Gen Psychiatry 2005; 62: 10321041.
  • 15
    Wagner A,Greer P,Bailer UF,Frank GK,Henry SE,Putnam K, et al. Normal brain tissue volumes after long-term recovery in anorexia and bulimia nervosa. Biol Psychiatry 2006; 59: 291293.
  • 16
    First M,Spitzer R,Gibbon M,Williams J. Structured Clinical Interview for Axis I Disorders-Patient Edition. New York, NY: Biometrics Research, New York State Psychiatric Institute, 1996.
  • 17
    Beck A,Ward C,Mendelson M. An inventory for measuring depression. Arch Gen Psychiatry 1961; 3: 461471.
  • 18
    Spielberger C,Gorsuch R,Lushene R,Vagg P,Jacobs G. Manual for the State-Trait Anxiety Inventory (STAIForm Y). Palo Alto, CA: Consulting Psychologists Press, 1983.
  • 19
    Garner D. The Eating Disorders Inventory-2 Manual. Odessa, FL: Psychological Assessment Resources, 1991.
  • 20
    Goodman WK,Price LH,Rasmussen SA,Mazure C,Fleischmann RL,Hill CL, et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 1989; 46: 10061011.
  • 21
    Goodman WK,Price LH,Rasmussen SA,Mazure C,Delgado P,Heninger GR, et al. The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry 1989; 46: 10121016.
  • 22
    Barratt ES. The biological basis of impulsiveness: The significance of timing and rhythm. Personality Individual Diff 1983; 4: 387391.
  • 23
    Cloninger C,Przybeck T,Svrakic DRW. The temperament and character inventory (TCI): A guide to its development and use. St. Louis: Center for Psychology of Personality, Washington University, 1994.
  • 24
    Logan J. A review of graphical methods for tracer studies and strategies to reduce bias. Nuclear Med Biol 2003; 30: 833844.
  • 25
    Ginovart N,Wilson AA,Meyer JH,Hussey D,Houle S. Positron emission tomography quantification of [(11)C]-DASB binding to the human serotonin transporter: Modeling strategies. J Cereb Blood Flow Metab 2001; 21: 13421353.
  • 26
    Logan J,Fowler JS,Volkow ND,Wang GJ,Ding YS,Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996; 16: 834840.
  • 27
    Innis RB,Cunningham VJ,Delforge J,Fujita M,Gjedde A,Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007; 27: 15331539.
  • 28
    Parsey RV,Kent JM,Oquendo MA,Richards MC,Pratap M,Cooper TB, et al. Acute occupancy of brain serotonin transporter by sertraline as measured by [11C]DASB and positron emission tomography. Biol Psychiatry 2006; 59: 821828.
  • 29
    Hoh C. Independent component analysis minimizing the mutual information criteria in polar coordinates. Presented at International Multi-conference on Complexity, Informatics, and Cybernetics, Orlando, Florida, 2010.
  • 30
    Wu HM,Hoh CK,Choi Y,Schelbert HR,Hawkins RA,Phelps ME, et al. Factor analysis for extraction of blood time-activity curves in dynamic FDG-PET studies. J Nuclear Med 1995; 36: 17141722.
  • 31
    Jenkinson M,Bannister P,Brady M,Smith S. Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage 2002; 17: 825841.
  • 32
    Walsh BT. Psychopharmacologic treatment of bulimia nervosa. J Clin Psychiatry 1991; 52 ( Suppl): 3438.
  • 33
    Steiger H,Joober R,Israel M,Young SN,Ng Ying Kin NM,Gauvin L, et al. The 5HTTLPR polymorphism, psychopathologic symptoms, and platelet [3H-] paroxetine binding in bulimic syndromes. Int J Eat Disord 2005; 37: 5760.
  • 34
    Cannon DM,Ichise M,Rollis D,Klaver JM,Gandhi SK,Charney DS, et al. Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [11C]DASB; comparison with bipolar disorder. Biol Psychiatry 2007; 62: 870877.
  • 35
    Meyer JH. Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J Psychiatry Neurosci 2007; 32: 86102.
  • 36
    Yamamoto S,Onoe H,Tsukada H,Watanabe Y. Effects of increased endogenous serotonin on the in vivo binding of [11C]DASB to serotonin transporters in conscious monkey brain. Synapse 2007; 61: 724731.
  • 37
    Bailer U,Bloss CS,Frank GK,Price JC,Meltzer CC,Mathis C, et al. 5-HT1A Receptor binding is increased after recovery from bulimia nervosa compared to control women and is associated with behavioral inhibition in both groups. Int J Eating Disord, 2010 Sept. 24; [Epub ahead of print (DOI: 10.1002/eat.20843)].
  • 38
    Praschak-Rieder N,Willeit M,Wilson AA,Houle S,Meyer JH. Seasonal variation in human brain serotonin transporter binding. Arch Gen Psychiatry 2008; 65: 10721078.
  • 39
    Kalbitzer J,Erritzoe D,Holst KK,Nielsen FA,Marner L,Lehel S, et al. Seasonal changes in brain serotonin transporter binding in short serotonin transporter linked polymorphic region-allele carriers but not in long-allele homozygotes. Biol Psychiatry 2010; 67: 10331039.
  • 40
    Ruhe HG,Booij J,Reitsma JB,Schene AH. Serotonin transporter binding with [123I]beta-CIT SPECT in major depressive disorder versus controls: Effect of season and gender. Eur J Nucl Med Mol Imaging 2009; 36: 841849.